Moderna Inc.’s settlement to end a lawsuit over technology used in its Covid-19 vaccine caps its potential exposure at $2.25 ...

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) stock added almost 9% after it was announced that the drugmaker has agreed to pay up to $2.25 billion to settle a global patent infringement lawsuit brought by ...

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used ...

In early February 2026, the U.S. District Court for the District of Delaware denied Moderna’s bid for summary judgment in a multi-billion-dollar patent infringement case brought by Arbutus Biopharma ...

Moderna Inc. agreed to pay $950 million to settle litigation related to the delivery technology behind its Covid shot, ...

The settlement, which requires Moderna to pay the plaintiffs $950 million upfront plus up to $1.3 billion in contingent commitments, is an outcome “better than feared,” according to analysts.

Moderna Inc. MRNA shares are up during Wednesday’s premarket session following a settlement agreement with Arbutus Biopharma Corporation ABUS and Roivant Inc.’s ROIV Genevant Sciences. Moderna Settles ...

A key U.S. federal vaccine advisory panel has dropped a push against COVID mRNA vaccines, the Washington Post reported on ...

Moderna will pay up to $2.25B to settle a patent lawsuit over lipid nanoparticle technology used in its COVID-19 vaccine.

Moderna Inc agreed to pay US$950 million to settle litigation related to the delivery technology behind its Covid-19 shot, removing a looming financial risk for the struggling vaccine maker.